Zimmer Closes In On Centerpulse; “Disciplined” S&N Scanning Other Targets
This article was originally published in The Gray Sheet
Executive Summary
Smith & Nephew will pursue growth in the endoscopy and wound management areas, following its decision not to raise a $2.3 bil. cash-and-stock bid for Centerpulse
You may also be interested in...
People In Brief
Cerus brings in new blood: William Dawson joins firm Aug. 9 as chief financial officer. Previously, Dawson served as CFO at biopharmaceutical firm Dynavax Technologies Corp., where he spearheaded the creation and $61 mil. IPO of Dynavax Asia. Dawson replaces Gregory Schafer, who had been Cerus' CFO since 1999. Cerus recently inked a marketing and distribution agreement with BioOne Corp for Asian commercialization of its Intercept blood system for pathogen inactivation. The Concord, Calif.-based concern's efforts to bring Intercept to the U.S. market encountered delays when it chose to halt its Phase III trial for the red blood cell pathogen reduction program after two patients developed antibodies (1"The Gray Sheet" March 29, 2004, p. 14)...
People In Brief
Cerus brings in new blood: William Dawson joins firm Aug. 9 as chief financial officer. Previously, Dawson served as CFO at biopharmaceutical firm Dynavax Technologies Corp., where he spearheaded the creation and $61 mil. IPO of Dynavax Asia. Dawson replaces Gregory Schafer, who had been Cerus' CFO since 1999. Cerus recently inked a marketing and distribution agreement with BioOne Corp for Asian commercialization of its Intercept blood system for pathogen inactivation. The Concord, Calif.-based concern's efforts to bring Intercept to the U.S. market encountered delays when it chose to halt its Phase III trial for the red blood cell pathogen reduction program after two patients developed antibodies (1"The Gray Sheet" March 29, 2004, p. 14)...
S&N Preps For Potential Ceramic Hip Launch At March AAOS Meeting
Smith & Nephew expects PMA approval of a ceramic-on-ceramic hip by the second quarter of 2004, according to Orthopedics Division President David Illingworth